作为是全球最大的制药公司之一,诺和诺德近年来一直受到市场广泛关注。2025年第一季度,司美格鲁肽全球销售额攀上84.1亿美元,超过此前的不败神话K药(Keytruda可瑞达),坐上了全球“药王”宝座。相比K药,在减肥药适应症的推动之下,司美格鲁肽增长势头仍然不断攀升,展现出强劲的扩张潜力。对于诺和诺德而言,时间就是金钱。诺和诺德数字化战略主管Waheed Jowiya曾表示,“药物每早一天进入市场...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.